PALO ALTO, CALIF., May 2, 2022—Spectacles that use SightGlass Vision™ Diffusion Optics Technology™ have demonstrated efficacy in slowing the progression of myopia in children,¹ based on 24-month interim data from its pivotal clinical trial data presented this week at ARVO 2022.
Two Year Effectiveness of a Novel Myopia Management Spectacle Lens with Full Time Wearers (Rappon J, Neitz J, Neitz M , Chung C, Chalberg T) is a featured presentation at the annual conference, which is attended by thousands of the world’s most respected ophthalmology, optometry, and vision science researchers.
An analysis of full-time wearers—children ages 6-10 at initiation whose parents reported that they did not remove the study spectacles for near vision activities —showed statistically significant improvements between groups using Diffusion Optics Technology™ lenses and the control. Axial length exhibited a 0.21 mm difference, and the spherical equivalent refraction difference was 0.52 D.
Study investigators enrolled, randomized, and dispensed the lenses to 256 eligible children across 14 clinical trial sites in the United States and Canada—a geographical distinction compared to most other myopia-related spectacle lens studies. At the time of enrollment, subjects were six to 10 years old having myopia between -0.75 D and -4.50 D. The CYPRESS trial is now in its third year.
With a mean age of 8.1 years at screening, the CYPRESS cohort is younger than children in other well-known myopia management studies.²,³,⁴ Given the higher likelihood of spectacles-based interventions for younger children, this study parameter should help build confidence in prescribers and families alike. Additional analysis of younger wearers will be presented at NCC 2022 this June.
Spectacle lenses using patent-protected SightGlass Vision™ Diffusion Optics Technology™️ incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children.
“With their unique mechanism of action, Diffusion Optics Technology™ spectacle lenses represent a promising new approach to myopia control,” said Andrew Sedgwick, CEO of SightGlass Vision. “We’re enthusiastic about sharing more detail from the two-year interim results, which will further support our development efforts and ongoing commercialization activities in select markets.”
The last several decades have seen a steady rise in the prevalence of myopia worldwide, notably under the effect of lifestyle changes. Today affecting 2.6 billion people globally, it is estimated that nearly 5 billion people – half the world’s population – will be myopic by 2050.⁵ Myopia is the leading cause of visual impairment in children and, over time, may contribute to an increased risk of developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia.⁶
About SightGlass Vision
SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children. The treatment is currently in year three of a pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.
Mike McDougall, APR, Fellow PRSA
McDougall Communications for SightGlass Vision
+1-585-434-2150 or email@example.com
Please note that our products are not available for sale or distribution in every country in the world.
Our products are not available for sale in the U.S.